Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Terminated Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Primary CDI

NCT03795233
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

NCT00871949
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

NCT00475930
View directory record Official record
Conditions
Staphylococcus Aureus, Community-acquired Infections, Staphylococcal Skin Infections
Interventions
2% chlorhexidine gluconate (CHG) impregnated cloths, Comfort Bath cloths (placebo cloths)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
1,563 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Quantico, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 29, 2026, 8:05 PM EDT
Completed No phase listed Observational

Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis

NCT00620984
View directory record Official record
Conditions
Mastitis, Staphylococcus Aureus, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Female only
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of Standard Drugs for Mycobacterium Avium Complex

NCT04287049
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 8:05 PM EDT
Completed No phase listed Observational

Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis

NCT03055728
View directory record Official record
Conditions
Streptococcal Infections
Interventions
Rapid strep antigen detection test, throat culture
Diagnostic Test
Lead sponsor
Georgetown University
Other
Eligibility
2 Years to 20 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 29, 2026, 8:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenic Mechanisms in C Diff Infection and Colitis

NCT01930032
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 29, 2026, 8:05 PM EDT
Not listed Not applicable Interventional

Vitamin A Supplementation in Preterm Infants

NCT00063596
View directory record Official record
Conditions
Infant, Premature
Interventions
Vitamin A supplementation
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 3 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Not applicable Interventional Results available

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

NCT02798354
View directory record Official record
Conditions
Diagnostic Errors
Interventions
Quality Improvement Collaborative
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
26 Years and older
Enrollment
13,853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

NCT00148941
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
4,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
24
States / cities
Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 29, 2026, 8:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

NCT00859677
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 29, 2026, 8:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

NCT07135453
View directory record Official record
Conditions
Vaccine, Pneumococcal Disease
Interventions
Pneumococcal Vaccine
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

NCT01861457
View directory record Official record
Conditions
Infectious Disease
Interventions
Nozin® Nasal Sanitizer®, Placebo
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

NCT01230957
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
40 Years to 75 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
30
States / cities
Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 29, 2026, 8:05 PM EDT
Not listed Phase 2 Interventional

Gut Microbiota Changes After Fecal Microbiota Transplantation

NCT02557685
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

NCT03202693
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00269399
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 29, 2026, 8:05 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
9,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
142
States / cities
Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

NCT03603665
View directory record Official record
Conditions
Botulism
Interventions
NTM-1633, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 29, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

NCT01582711
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine
Behavioral · Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 29, 2026, 8:05 PM EDT